Of the remaining 79 studies, the full text was screened and 66 studies were excluded for lack of follow-up, no information about prognosis, not restricted to advanced NSCLC patients, non-English literature, not restricted to KRAS or EGFR (exon19 and exon21) mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.